Funds Raised: $45 Million in Series A for Developing a Universal Influenza Vaccine (Centivax)
South San Francisco-based biotechnology company Centivax has made significant strides in the development of a groundbreaking universal flu vaccine, known as Centi-Flu. The company has recently closed a $45 million Series A funding round, led by Future Ventures, to propel this vaccine candidate into clinical trials.
The funding round, which also includes investments from NFX, BOLD Capital Partners, Base4 Capital, Kendall Capital Partners, Amplify Partners, and more, is crucial for advancing Centivax's universal flu vaccine into the clinical phase. This investment underscores the potential and interest in the vaccine's development.
Centivax's universal flu vaccine is developed using mRNA technology, a promising approach for creating broad-spectrum vaccines. The company plans to bring the vaccine into clinical trials in about eight months, marking a significant step towards its commercialization.
The universal flu vaccine targets a critical healthcare need, as the flu vaccine market is over $7 billion annually. A successful universal flu vaccine could significantly reduce the burden of influenza globally. Unlike traditional flu vaccines that provide protection against specific strains, Centivax's vaccine aims to offer broader protection against multiple flu strains. This could reduce the need for annual flu shots and improve public health outcomes.
In addition to the flu vaccine, Centivax is developing anti-venoms and anti-infectives, further expanding its portfolio and potential impact on global health. Dr. Jacob Glanville, PhD, co-founder and CEO of Centivax, is excited about the possibilities that universal vaccines can bring to medicine, stating that they can take us further in medicine.
Notable additions to Centivax's team include Dr. Emini, PhD, formerly of the Gates Medical Research Institute, Pfizer, and Merck, who has joined Centivax's board. Dr. Emini is particularly excited about Centivax's approach to the design and development of a truly universal influenza vaccine.
The funds will support Centivax's first clinical candidate, a universal flu vaccine in CMC development. In preclinical studies, Centivax's technology consistently induced universal immunity to all tested influenza viruses, including the 2024-2025 H5N1 'bird flu'. This unique and creative approach, as expressed by Dr. Emini, has considerable potential for successfully achieving a goal that has proven elusive to date.
Centivax secured $24 million from non-dilutive awards, including a $2 million Grand Challenge grant from the Bill & Melinda Gates Foundation. The financing, led by Future Ventures, carries the company through first-in-human studies, a value-inflection point that will catalyze the next phase of growth for Centivax and move the first universal flu vaccine one step closer to market.
Dr. Jerald Sadoff, MD, Chief Medical Officer of Centivax, has played a key role in developing the Gardasil vaccine, which reduced the national incidence of multiple cancer types and functioned as an anti-cancer vaccine. Sadoff also spearheaded the development of Zostavax vaccine, which has recently been demonstrated to reduce Alzheimer's and heart disease. Sadoff's expertise and achievements further bolster Centivax's mission to revolutionize the field of vaccinology.
In summary, Centivax's universal flu vaccine development has the potential to transform the way we approach influenza prevention by offering a more comprehensive and sustainable solution. With the recent funding, the company is poised to bring its innovative vaccine candidate one step closer to market.
- The $45 million Series A funding round, led by Future Ventures, signals finance and investing interest in Centivax's universal flu vaccine development, a promising health-and-wellness breakthrough that leverages mRNA technology and aims to provide broader protection against multiple flu strains.
- Centivax's technology, which consistently induced universal immunity in preclinical studies, is not only a crucial advancement in science but also a potential game-changer in the medical-conditions sector, aiming to significantly reduce the global burden of influenza.
- The company's strategic moves, such as the recruitment of Dr. Emini, a renowned scientist with experience from Gates Medical Research Institute, Pfizer, and Merck, underscore the company's commitment to technology-driven innovation in the field of health-and-wellness, particularly in the multi-billion dollar flu vaccine market.
){kind=link}